Sotera Health Company

Fundamentals5.0
Price Action4.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Strong Margins
  • High Leverage
  • Tight Coverage

AI
AI Summary

5.0

SHC's Q1 strength confirms the core business is healthy, but the real investment question is whether management can turn EBITDA into sustained free cash flow fast enough to offset high leverage and the Warburg/GTCR secondary-sale overhang, because without that the improving operations may still fail to drive multiple expansion.

Execution
Leverage
Overhang‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Strong Margins
  • High Leverage
  • Tight Coverage

SHC has solid margins and cash generation, but heavy leverage, intangible-heavy assets, and a demanding valuation make it a cautious hold. ക

Leverage
Valuation

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Near support
  • Fading rebounds

SHC has weakened into a short-term downtrend over the last month, sitting near $15.27-$15.33 support with fading rebounds, and a break below support would confirm further downside while a move above $15.81 would signal improvement.

bearish
support
Support Level: $15.27-$15.33
Resistance Level: $15.78-$15.81

Orderly decline from $16.30 to $15.27 with repeated failed rebounds

Sentiment & News

6.0

Key News Insights:

  • Earnings Beat
  • CEO Transition
  • Share Overhang

Sotera Health delivered a strong Q1 beat with positive net income and reaffirmed full-year guidance, while also announcing a CEO transition and a large secondary share sale that add near-term overhangs.

earnings
leadership

The improved operating performance is supportive for the stock, but the secondary offering and leadership change may temper near-term upside